BioNTech beginnt Phase-1-Studie mit prophylaktischem Impfstoffkandidaten BNT163 gegen Herpes-Simplex-Virus-2 Erste klinische Studie untersucht Sicherheit und Immunogenität des prophylaktischen Herpes-Virus-Impfstoffkandidaten BNT163 erstmalig am MenschenBNT163 ist der erste Kandidat aus BioNTechs...

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163 First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine...

AYRO Announces Results of Annual Meeting of Stockholders and Provides Summary of Business Update AUSTIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- AYRO, Inc. (Nasdaq: AYRO) (“AYRO” or the “Company”), a designer and manufacturer of electric, purpose-built delivery vehicles and solutions for micro...

DSG Global Inc. and Imperium Motor Company Experience Successful Twelve Days at LA Auto Show with Strong Sales and Media Recognition SURREY, British Columbia, Dec. 01, 2021 (GLOBE NEWSWIRE) -- DSG Global, Inc. (OTCQB: DSGT) ("DSGT" or the "Company") and Imperium Motor Company are pleased to announce the completion of a much...

CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure Oakland, CA, Nov. 18, 2019 (GLOBE NEWSWIRE) -- At the 2019 International Symposium on Neurovirology, Excision BioTherapeutics, a gene therapy company focusing on curing viral infectious diseases,...